Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,730,000 | 3,105,900 | 2,885,600 | 2,193,700 | 1,617,800 |
| Marketable Securities | 8,114,800 | 4,636,400 | 2,809,100 | 1,393,300 | 1,596,500 |
| Receivables | 5,667,300 | 5,328,700 | 6,036,500 | 4,114,700 | 2,785,600 |
| Inventories | 2,580,500 | 2,401,900 | 1,951,300 | 1,916,600 | 1,415,500 |
| TOTAL | $19,479,200 | $15,884,100 | $14,014,900 | $9,779,100 | $7,689,100 |
| Non-Current Assets | |||||
| PPE Net | 4,146,400 | 3,763,000 | 3,482,200 | 3,221,600 | 2,890,400 |
| Investments And Advances | 5,396,500 | 6,591,800 | 6,838,000 | 3,135,600 | 3,256,800 |
| Intangibles | 1,038,600 | 915,500 | 6,700 | 0 | 0 |
| Other Non-Current Assets | 3,019,500 | 2,060,100 | 1,093,000 | 1,027,000 | 968,901 |
| TOTAL | $13,601,000 | $13,330,400 | $11,419,900 | $7,384,200 | $7,116,101 |
| Total Assets | $33,080,200 | $29,214,500 | $25,434,800 | $17,163,300 | $14,805,200 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 606,600 | 589,200 | 564,000 | 475,500 | 418,100 |
| Other current liabilities | 2,357,900 | 2,074,200 | 2,206,800 | 1,644,200 | 1,296,400 |
| TOTAL | $3,423,400 | $3,141,300 | $3,932,500 | $2,697,400 | $2,096,600 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,982,900 | 1,981,400 | 1,980,000 | 1,978,500 | 0 |
| Deferred Revenues | 458,900 | 477,900 | 442,000 | 577,700 | 382,100 |
| Other Non-Current Liabilities | 854,100 | 638,000 | 680,200 | 687,100 | 799,700 |
| TOTAL | $3,683,700 | $3,409,200 | $2,733,500 | $3,440,600 | $1,618,900 |
| Total Liabilities | $7,107,100 | $6,550,500 | $6,666,000 | $6,138,000 | $3,715,500 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 109,762 | 109,326 | 108,539 | 107,132 | 110,020 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 27,260,300 | 23,306,700 | 18,968,300 | 10,893,000 | 7,379,800 |
| Other shareholders' equity | -81,300 | -239,100 | -26,100 | 29,000 | 21,200 |
| TOTAL | $25,973,100 | $22,664,000 | $18,768,800 | $11,025,300 | $11,089,700 |
| Total Liabilities And Equity | $33,080,200 | $29,214,500 | $25,434,800 | $17,163,300 | $14,805,200 |